

CLAIMS

1. Use of a composition comprising a complex of IGF-1 and IGFBP-3, in the manufacture of a medicament for the prevention of IVH in a preterm infant at a gestational age of 23 to 26 weeks, wherein the complex is to be administered via continuous infusion a dose of 350-500µg/Kg/day, for a period of at least 7 days, such that plasma levels of IGF-1 are maintained within the therapeutic range 28µg/L to 109µg/L during the treatment period, wherein
after exclusion of baseline assessment timepoint more than 60% of those infants receiving treatment are IVH free, and
pathological fluctuations in blood osmolarity are stabilised and treated preterms have an overall mortality benefit from all causes.
2. Use according to claim 1, wherein the preterm infant is 23 to 25 weeks gestational age.
3. Use according to any preceding claim, wherein 87.5% of the treated patient population 26 weeks gestational age are IVH free.
4. Use according to any preceding claim, wherein a treated preterm has stabilisation of vital functions in the presence of hyperosmolarity.
5. Use according to claim 4, wherein the vital function is selected from: breathing, heart rate and blood pressure.
6. Use according to any preceding claim, wherein the preterm infants are to be treated for at least 2 to 6 weeks.
7. Use according to any preceding claim, wherein treatment is to be continued until 32, 33 or 34 weeks gestational age.